Michel Klaassen, Netherlands
Inreda Diabetic R&DPresenter of 1 Presentation
CASE REPORT ON THE PERFORMANCE OF LONG-TERM USAGE OF AN INTEGRATED BIHORMONAL ARTIFICIAL PANCREAS IN DAILY LIFE
Abstract
Background and Aims
The founder of Inreda Diabetic, manufacturer of a fully-automated bihormonal artificial pancreas system (AP) suffers from type 1 diabetes himself. After further improvements of the AP tested before in ten patients at home, he started AP therapy in November 2018 and has been using it ever since. To our knowledge a bihormonal AP has not yet been used for such a long period.
Methods
This case report describes self-experimentation during daily life. Patient’s treatment before using the AP consisted of multiple daily insulin injections and SMBG. The AP, which uses two sensors that continuously monitor the glucose level and administers insulin or glucagon accordingly, stores the glucose values and sends this to a secured server. HbA1c values were measured during regular hospital visits.
Results
Presented values are median [IQR] values over the period from November 18, 2018 until September 30, 2019. The daily time in range (3.9-10 mmol/l) was 92.6 [88.1 – 96.7]% , the median glucose was 7.1 [6.7 – 7.5] mmol/l. The daily time in hypoglycemia was 0.0 [0.0 – 1.0]%. Last measured HbA1c before AP therapy was 66 mmol/mol. Six weeks after the start of AP therapy the HbA1c was 54 mmol/mol and then remained stable.
Conclusions
The bihormonal AP provides good long-term glucose control in this patient. The improved HbA1c values indicate clear health benefits for this patient. Although long-term data is only available for one patient, we expect that the AP will provide good long-term glucose control in other patients with type 1 diabetes as well.